

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	NeuroScientific Biopharmaceuticals Limited
<b>ABN</b>	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Brian Leedman
<b>Date of last notice</b>	3 March 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	As director and shareholder of Tashtech Pty Ltd.  As director of Thunderous Pty Ltd ATF Thunderous Superannuation Fund.
<b>Date of change</b>	13 May 2021

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held prior to change</b>	<p><u>Direct:</u> 2,138,130 Ordinary shares</p> <p>250,000 Class C Performance Shares</p> <p>250,000 Class D Performance Shares</p> <p>250,000 Class E Performance Shares</p> <p>1,200,000 Unlisted options (exercisable at \$0.30 on or before 17 December 2022)</p> <p><u>Indirect:</u> 91,875 Ordinary shares</p> <p>500,000 Unlisted Options (exercisable at \$0.40 on or before 15 January 2024)</p>
<b>Class</b>	Ordinary Shares, unlisted options and performance
<b>Number acquired</b>	<u>Indirect:</u> 123,447 ordinary shares purchased on market
<b>Number disposed</b>	None
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$27,806.13 consideration paid for purchase of 123,447 ordinary shares
<b>No. of securities held after change</b>	<p><u>Direct:</u> 2,138,130 Ordinary shares</p> <p>250,000 Class C Performance Shares</p> <p>250,000 Class D Performance Shares</p> <p>250,000 Class E Performance Shares</p> <p>1,200,000 Unlisted options (exercisable at \$0.30 on or before 17 December 2022)</p> <p><u>Indirect:</u> 215,322 Ordinary shares</p> <p>500,000 Unlisted Options (exercisable at \$0.40 on or before 15 January 2024)</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trade

+ See chapter 19 for defined terms.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	-
<b>Interest after change</b>	-

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	-
<b>If prior written clearance was provided, on what date was this provided?</b>	-

---

<sup>+</sup> See chapter 19 for defined terms.